AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multicenter, open-label, randomized study of neoadjuvant immune-checkpoint
blockade therapy (AK104) combining with TACE for resectable hepatocellular carcinoma. The
purpose is to investigate the efficacy and safety of this therapeutic regimen to reduce the
risk of postoperative recurrence in resectable HCC patients with a high risk of recurrence.